問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Recruiting

List

537Cases

2025-03-01 - 2028-04-30

Phase I

Active
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    Subcutaneous injection Capsule

Participate Sites
4Sites

Recruiting4Sites

2025-04-01 - 2030-06-18

Phase III

Active
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Injectables Injectables Injectables

Participate Sites
8Sites

Recruiting8Sites

2025-05-01 - 2027-11-30

Phase III

Active
A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria

  • Condition/Disease

    Chronic Kidney Disease 、Proteinuria

  • Test Drug

    Tablets Tablets Tablets Granules for suspension Granules for suspension

Participate Sites
6Sites

Recruiting6Sites

2025-05-01 - 2028-05-31

Phase I

Not yet recruiting
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 Inhibitor, as Monotherapy and in Combination With Other Agents, in Participants With Haematologic Neoplasms

  • Condition/Disease

    Haematologic Neoplasms

  • Test Drug

    N/A

Participate Sites
3Sites

Recruiting3Sites

2025-05-01 - 2028-07-31

Active
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
6Sites

Recruiting6Sites

2025-06-13 - 2030-06-30

Active
An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

  • Condition/Disease

    Primary Membranous Nephropathy

  • Test Drug

    Injectable frozen powder

Participate Sites
10Sites

Recruiting10Sites

2025-06-30 - 2027-07-28

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  • Condition/Disease

    Atopic Hand and Foot Dermatitis

  • Test Drug

    Prefilled Injectable

Participate Sites
7Sites

Recruiting7Sites

2025-07-01 - 2029-02-12

Phase II

Active
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  • Condition/Disease

    Metastatic Hormone-sensitive Prostate Cancer

  • Test Drug

    Tablets

Participate Sites
2Sites

Recruiting2Sites

2025-08-20 - 2029-02-17

Phase III

Active
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Carcinoma, Non-Small-Cell Lung 、Carcinoma, Non-Small-Cell Lung (NSCLC)

  • Test Drug

    Frozen Crystal Injection Injection

Participate Sites
8Sites

Recruiting8Sites

2025-09-10 - 2028-06-13

Phase I

Not yet recruiting
A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  • Condition/Disease

    Advanced Clear Cell Renal Cell Carcinoma

  • Test Drug

    Frozen Crystal Injection Film-Coated Tablets

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 54
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB